What are the strengths and weaknesses of conventional measures of RA disease activity (i.e., ACR scores) as compared to patient-reported outcomes (PROS)? And what is the role of treat-to-target?

What are the strengths and weaknesses of conventional measures of RA disease activity (i.e., ACR scores) as compared to patient-reported outcomes (PROS)? And what is the role of treat-to-target?

What are the strengths and weaknesses of conventional measures of RA disease activity (i.e., ACR scores) as compared to the increasingly important patient-reported outcomes (PROS) that are being used in clinical trials? And what is the role of treat-to-target?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Eric Ruderman, MD

Eric Ruderman, MD

Professor of Medicine
Division of Rheumatology
Northwestern University, Feinberg School of Medicine
Chicago, Illinois